Ultromics AI platform to expand trials to 20 NHS hospitals

A British AI platform for assisting with the diagnosis of heart disease will enter trials with 20 NHS hospitals before the end of 2018, after securing £10 million in first-round funding. UK start-up Ultromics has developed echocardiography analysis technology called Topological Analysis that claims to reduce errors diagnosing coronary artery disease by as much as 75%. The machine learning platform is currently being trialled at six NHS hospitals, and after garnering interest from a number of trusts earlier this year, Ultromics has secured investment to expand trials to additional UK sites. The fundraising was led by Oxford Sciences Innovation (OSI), with Neptune, RT Ventures, GT Healthcare, Tanarra, Fushia and personal investors Andre Crawford-Brunt and Dieter Spälti also participating. The £10 million investment will be used to bring the technology to market in the USA, with Ultromics hoping to make it available in the UK from early 2019.